JP2008521827A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521827A5
JP2008521827A5 JP2007543584A JP2007543584A JP2008521827A5 JP 2008521827 A5 JP2008521827 A5 JP 2008521827A5 JP 2007543584 A JP2007543584 A JP 2007543584A JP 2007543584 A JP2007543584 A JP 2007543584A JP 2008521827 A5 JP2008521827 A5 JP 2008521827A5
Authority
JP
Japan
Prior art keywords
agonist
receptor modulator
ethyl
phenyl
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007543584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521827A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/043044 external-priority patent/WO2006058316A1/en
Publication of JP2008521827A publication Critical patent/JP2008521827A/ja
Publication of JP2008521827A5 publication Critical patent/JP2008521827A5/ja
Withdrawn legal-status Critical Current

Links

JP2007543584A 2004-11-29 2005-11-28 Ｓ１ｐ受容体アゴニストの投与レジメン Withdrawn JP2008521827A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63148304P 2004-11-29 2004-11-29
PCT/US2005/043044 WO2006058316A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012040574A Division JP2012107059A (ja) 2004-11-29 2012-02-27 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2013043351A Division JP2013129664A (ja) 2004-11-29 2013-03-05 Ｓ１ｐ受容体アゴニストの投与レジメン

Publications (2)

Publication Number Publication Date
JP2008521827A JP2008521827A (ja) 2008-06-26
JP2008521827A5 true JP2008521827A5 (enExample) 2009-02-05

Family

ID=36046868

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007543584A Withdrawn JP2008521827A (ja) 2004-11-29 2005-11-28 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2012040574A Withdrawn JP2012107059A (ja) 2004-11-29 2012-02-27 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2013043351A Withdrawn JP2013129664A (ja) 2004-11-29 2013-03-05 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2014266267A Pending JP2015061883A (ja) 2004-11-29 2014-12-26 Ｓ１ｐ受容体アゴニストの投与レジメン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012040574A Withdrawn JP2012107059A (ja) 2004-11-29 2012-02-27 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2013043351A Withdrawn JP2013129664A (ja) 2004-11-29 2013-03-05 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2014266267A Pending JP2015061883A (ja) 2004-11-29 2014-12-26 Ｓ１ｐ受容体アゴニストの投与レジメン

Country Status (21)

Country Link
US (3) US20090275553A1 (enExample)
EP (3) EP2384749A1 (enExample)
JP (4) JP2008521827A (enExample)
KR (4) KR20070085465A (enExample)
CN (2) CN102600472A (enExample)
AU (1) AU2005309378B2 (enExample)
BR (1) BRPI0518674A2 (enExample)
CA (1) CA2589265A1 (enExample)
ES (1) ES2495690T3 (enExample)
IL (2) IL183134A0 (enExample)
MA (1) MA29034B1 (enExample)
MX (1) MX2007006373A (enExample)
NO (2) NO20072401L (enExample)
NZ (2) NZ590054A (enExample)
PL (1) PL1819326T3 (enExample)
PT (1) PT1819326E (enExample)
RU (2) RU2478384C2 (enExample)
SG (2) SG158096A1 (enExample)
TN (1) TNSN07209A1 (enExample)
WO (1) WO2006058316A1 (enExample)
ZA (1) ZA200703328B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0514316A (pt) 2004-08-13 2008-06-10 Praecis Pharm Inc métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
EP2384749A1 (en) * 2004-11-29 2011-11-09 Novartis AG Dosage regimen of an S1P receptor agonist
NZ566137A (en) * 2005-09-09 2011-05-27 Novartis Ag The use of diphenyl thioether derivatives to treat autoimmune diseases
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2142184B1 (en) 2007-05-04 2018-10-24 Novartis AG Use of s1p receptor modulator
CA2716448A1 (en) * 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
EP2305305A4 (en) * 2008-05-20 2013-02-13 Kyorin Seiyaku Kk MEDIUM FOR INTRODUCTION / MAINTENANCE OF THE REMISSION
RU2521286C2 (ru) * 2008-07-23 2014-06-27 Новартис Аг Модуляторы рецептора сфингозин-1-фосфата (s1p) и их применение для лечения воспаления мышечной ткани
CA2733508A1 (en) * 2008-08-18 2010-02-25 David Leppert Compounds for the treatment of peripheral neuropathies
AU2009327405A1 (en) * 2008-12-18 2011-06-30 Novartis Ag New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
HRP20131106T1 (hr) * 2008-12-18 2013-12-20 Novartis Ag Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
RU2011129229A (ru) * 2008-12-18 2013-01-27 Новартис Аг Новые соли
MX367667B (es) * 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
US20100160259A1 (en) * 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist
AU2015275246B2 (en) * 2008-12-22 2018-02-01 Novartis Ag Dosage regimen for a S1P receptor agonist
EP3831371A1 (en) 2009-09-29 2021-06-09 Novartis AG Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
WO2011138398A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
CA2852142A1 (en) * 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
HUE050733T2 (hu) 2012-08-17 2021-01-28 Actelion Pharmaceuticals Ltd Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
EP3054933A4 (en) 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
HUE057865T2 (hu) 2014-12-11 2022-06-28 Actelion Pharmaceuticals Ltd A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US10250466B2 (en) * 2016-03-29 2019-04-02 Juniper Networks, Inc. Application signature generation and distribution
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
WO1997024112A1 (en) * 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
EP2030614A1 (en) * 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
CZ200350A3 (cs) 2000-07-13 2003-05-14 Sankyo Company Limited Aminoalkoholové deriváty
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
MXPA03008755A (es) 2001-03-26 2004-02-18 Novartis Ag Derivados de 2-amino-propanol.
CZ20032647A3 (cs) * 2001-04-02 2004-09-15 Astrazeneca Ab Pevná farmaceutická kompozice obsahující 4-kyanotrifluor-3-(4-fluorfenylsulfonyl)-2-hydroxy-2-methylpropiono-m-toluidin a PVP
JP4679035B2 (ja) * 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
KR100913269B1 (ko) * 2001-09-27 2009-08-21 교린 세이야꾸 가부시키 가이샤 디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제
JP4152884B2 (ja) * 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
MXPA05003254A (es) * 2002-09-24 2005-06-08 Novartis Ag Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
EP1628967B1 (en) 2003-05-19 2014-04-09 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
EP2384749A1 (en) * 2004-11-29 2011-11-09 Novartis AG Dosage regimen of an S1P receptor agonist
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas

Similar Documents

Publication Publication Date Title
RU2007124327A (ru) Курс лечения с использованием агониста рецептора s1p
US6436938B1 (en) Combination treatment for depression
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
RU2008108887A (ru) Жидкие составы
JP2007507494A5 (enExample)
JP2019517587A5 (enExample)
JP2014505017A5 (enExample)
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
RU2008146816A (ru) Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
RU2009144846A (ru) Использование модулятора рецептора s1p
JP2004509857A5 (enExample)
JP2017512211A5 (enExample)
JP5941258B2 (ja) 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール
US20020165217A1 (en) Combination treatment for anxiety and depression
JP2007537287A5 (enExample)
RU2008108175A (ru) Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы
RU2010147881A (ru) ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА
US20020147206A1 (en) Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
RU2009138028A (ru) Новое профилактическое и/или лекарственное средство против невропатической боли
JP2005511571A5 (enExample)
WO2014008379A2 (en) Diamine and meglumine salt forms of fatty acids
JP2023549394A5 (enExample)
RU2009138032A (ru) Новое профилактическое и/или лекарственное средство против диабетической невропатии
RU2008108176A (ru) Комбинация соединений, которая может быть применена в лечении респеративных заболеваний, особенно хронического обструктивного заболевания легких (copd) и астмы
JP2003523995A5 (enExample)